Hepatitis E Diagnostic Tests Market Report: Market Size & Forecast 2026

The hepatitis diagnostic tests market spans a broad range of in vitro diagnostic products used to detect and monitor infections caused by hepatitis A, B, C, D, and E viruses. It encompasses immunoassays, molecular tests, point-of-care rapid tests, and laboratory-based diagnostic platforms. The wider hepatitis testing market, valued at approximately $3.47 billion in 2025, forms a substantial portion of the overall $6.4 billion hepatitis diagnostics space, reflecting both the clinical urgency of chronic hepatitis management and the scale of global screening initiatives.

• •Hepatitis E diagnostic tests market was estimated at approximately $57-66 million in 2024-2025
• •Projected to grow at a CAGR of roughly 4%-4.5%, reaching an estimated $75-93 million by 2030-2031
• •Point-of-care molecular diagnostics, a closely adjacent market, reached $4.30 billion in 2025 with a 10.5% CAGR

Rising prevalence of hepatitis infections, particularly in developing regions of Asia-Pacific and Sub-Saharan Africa, remains the primary market catalyst. Governments and international health organizations including the WHO have intensified hepatitis elimination campaigns, significantly expanding screening access in previously underserved populations. Advances in diagnostic technology, including rapid lateral flow assays, ELISA-based immunoassays, and real-time PCR molecular tests, have improved test accuracy, reduced turnaround time, and enabled decentralized testing outside traditional laboratory settings.

• •WHO 2030 hepatitis elimination targets are driving large-scale national screening and vaccination programs
• •Rising incidence of waterborne hepatitis E outbreaks in regions with inadequate sanitation infrastructure
• •Technological innovations in rapid and molecular diagnostics are making testing faster, more affordable, and more accessible

The market is segmented by test type, including ELISA (enzyme-linked immunosorbent assay), rapid immunochromatographic tests, real-time PCR, and immunoblot assays, each serving distinct clinical and public health use cases. End-users span hospitals, diagnostic laboratories, blood banks, and point-of-care settings, with growing demand in community health centers and field screening programs. Geographically, the Asia-Pacific region commands the largest share, driven by high disease burden in India, China, and Southeast Asia, while North America and Europe contribute through advanced laboratory infrastructure and strong reimbursement frameworks.

• •ELISA-based immunoassays remain the dominant technology segment, supplemented by fast-growing molecular testing platforms
• •Asia-Pacific leads regional demand due to high hepatitis E endemicity, followed by Africa and the Middle East
• •Blood screening and prenatal testing represent high-growth application segments within the market

What are the recent trends and outlook?

The market is moving decisively toward point-of-care and near-patient testing, as healthcare systems seek faster diagnosis and reduced laboratory burden. Molecular diagnostics, including isothermal amplification and next-generation sequencing technologies, are expected to capture growing market share as costs decline. Over the 2025-2034 forecast period, the broader hepatitis diagnostics market at a 4.06% CAGR reflects steady, sustained demand rather than explosive growth, a pattern consistent with mature diagnostic markets with entrenched clinical practices. The long-term outlook remains positive, underpinned by continued global health investment, technological innovation, and the expanding pipeline of hepatitis therapeutics that require companion diagnostic testing.

• •Point-of-care testing and home-based self-testing kits are emerging as significant growth opportunities
• •Artificial intelligence and digital pathology integration with diagnostic platforms is accelerating result interpretation and data management
• •Strategic partnerships between diagnostics manufacturers and public health agencies are expanding access in low- and middle-income countries